The evaluation of delayed CINV for the breast cancer patients during adjuvant dose-dense AC with steroid sparing and olanzapine 5mg regimen: A single center pilot study

The evaluation of delayed CINV for the breast cancer patients during adjuvant dose-dense AC with steroid sparing and olanzapine 5mg regimen: A single center pilot study - The evaluation of delayed CINV for the breast cancer patients during adjuvant dose-dense AC with steroid sparing and olanzapine 5mg regimen: A single center pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041605

Enrollment

Registered

2020-08-29

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with operable breast cancer 2) Patients in stages I-III. 3) Patients who are judged by their physicians to be eligible for dose-dense AC therapy (ddAC) as adjuvant perioperative chemotherapy. (4) Written informed consent, with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications to olanzapine (patients with a history of diabetes) 2) Patients considered to be inappropriate for the study participation, as judged by the primary physician.

Design outcomes

Primary

Measure	Time frame
CR rate in the delayed phase (24-120 hours after dose-dense AC)	—

Countries

Japan

Contacts

Public ContactManami Tada

Kansai Medical University Hospital Department of Breast Surgery

mnm.noa527@gmail.com0728040101

Outcome results